Pharvaris Announces FDA Clinical Hold on PHA121 Clinical Trials in the U.S.
August 22, 2022 06:50 ET
|
Pharvaris N.V.
ZUG, Switzerland, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary...
Pharvaris to Participate in H.C. Wainwright 1st Annual Hereditary Angioedema (HAE) Conference
July 14, 2022 08:10 ET
|
Pharvaris N.V.
ZUG, Switzerland, July 14, 2022 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent HAE attacks,...
Pharvaris to Host Virtual Expert Perspectives on HAE: Unmet Needs and Therapeutic Options Webinar on July 13
July 06, 2022 08:10 ET
|
Pharvaris N.V.
ZUG, Switzerland, July 06, 2022 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent HAE attacks,...
Pharvaris Announces Annual Meeting of Shareholders
June 14, 2022 08:10 ET
|
Pharvaris N.V.
ZUG, Switzerland, June 14, 2022 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent HAE attacks,...
Pharvaris Participates in the Kinin 2022 Conference
June 07, 2022 08:10 ET
|
Pharvaris N.V.
ZUG, Switzerland, June 07, 2022 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent HAE attacks,...
Pharvaris Supports HAE Community by Participating in Company-wide Activities Challenge for May 16th hae day :-)
May 16, 2022 08:10 ET
|
Pharvaris N.V.
ZUG, Switzerland, May 16, 2022 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent HAE attacks,...
Pharvaris Appoints Joan Schmidt, J.D., as Chief Legal Officer
May 11, 2022 08:15 ET
|
Pharvaris N.V.
Pharvaris’ executive team further strengthened by Ms. Schmidt’s deep international experience and biopharmaceutical industry tenure ZUG, Switzerland, May 11, 2022 (GLOBE NEWSWIRE) -- Pharvaris...
Pharvaris Reports First Quarter 2022 Financial Results and Provides Business Highlights
May 11, 2022 08:10 ET
|
Pharvaris N.V.
Target enrollment achieved in RAPIDe-1, Phase 2 on-demand study of PHVS416 for the treatment of HAE attacks; top-line data anticipated in 4Q22Enrollment underway in HAE CHAPTER-1, proof-of-concept...
Pharvaris to Participate in BofA Securities 2022 Healthcare Conference
May 05, 2022 16:10 ET
|
Pharvaris N.V.
ZUG, Switzerland, May 05, 2022 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent HAE attacks,...
Pharvaris to Participate in Upcoming April Investor Conferences
April 06, 2022 16:10 ET
|
Pharvaris N.V.
ZUG, Switzerland, April 06, 2022 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent HAE attacks,...